Prediction Protection: The Delaware Supreme Court’s Amylin Footnote

November 2009

Publication| Corporate Transactions| Corporate & Chancery Litigation

A footnote in the Delaware Supreme Court’s summary affirmance of the Chancery Court’s Amylin Pharmaceuticals decision made some corporate commentators question whether the Supreme Court was trending toward a substantive evaluation of the fiduciary duty of care. In our view, however, the Supreme Court’s footnote simply follows well established precedent and confirms that the Delaware courts will not require directors to predict the future in making business judgments.

  • sign up for our newsletter

    To keep our clients and friends updated on the latest legal news, Richards Layton distributes practice area e-alerts and newsletters. If you are interested in receiving these publications, please subscribe below.